首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1672767

神經生物標記市場：按生物標記類型、按應用、按最終用戶、按地區

Neurological Biomarkers Market, By Biomarker Type, By Application, By End User, By Geography

出版日期: 2025年02月19日 | 出版商:

Coherent Market Insights | 英文 174 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球神經生物標記市場規模估計為 96.4 億美元，預計到 2032 年將達到 231.2 億美元，2025 年至 2032 年的複合年成長率為 13.3%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	96.4億美元
效能資料	2020-2024	預測期	2025-2032
預測期：2025 年至 2032 年複合年成長率	13.30％	2032 年金額預測	231.2億美元

圖。

神經生物標記有助於客觀測量和評估正常的生物和致病過程。它們可用於檢測神經系統疾病、評估風險、追蹤疾病進展和測量對治療性介入的反應。阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病的發生率不斷增加，可能會推動對可靠的神經系統生物標記的需求。此外，對神經系統疾病精準醫療和伴同性診斷發展的日益關注也推動了市場的成長。然而，對疾病生物學的了解有限以及對生物標記使用缺乏共識對市場成長構成了挑戰。

市場動態

全球神經系統疾病生物標記市場的成長主要受到全球神經系統疾病盛行率上升的推動。根據世界衛生組織的資料，神經系統疾病影響全球超過10億人，是全球疾病負擔的主要原因。老年人口的不斷成長，使他們更容易患上這些疾病，這可能會推動需求。製藥公司對生物標記研究和藥物開發的投資增加可能會推動市場成長。然而，從目標識別到商業化的高昂藥物開發成本阻礙了生物標記進入新興市場。對於生物標記在診斷和臨床決策中的應用缺乏共識可能會阻礙市場的成長。加強跨學科研究的公私合作可能為市場成長提供機會。

研究的主要特點

本報告對全球神經生物標記市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
全球神經生物標記市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行的分析。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球神經生物標記市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。

公司簡介
- Thermo Fisher Scientific Inc.
- Merck &Co., Inc.
- Bio-Rad Laboratories, Inc.
- AbbVie Inc.
- QIAGEN NV
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Myriad RBM
- Quanterix Corporation
- PerkinElmer Inc.
- Fujirebio
- Alzheon, Inc.
- Diagenic ASA
- Psynova Neurotech Ltd
- Banyan Biomarkers, Inc.
- Cisbio Bioassays
- Athena Diagnostics
- Immuno-Biological Laboratories Co., Ltd.

第 10 章分析師建議

興衰
一致的機會地圖

第 11 章章節

參考
調查方法

簡介目錄

Product Code: CMI4586

Global Neurological Biomarkers Market is estimated to be valued at USD 9.64 Bn in 2025 and is expected to reach USD 23.12 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 9.64 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	13.30%	2032 Value Projection:	USD 23.12 Bn

Figure. Neurological Biomarkers Market Share (%), By Region 2025

Neurological biomarkers help in objectively measuring and evaluating normal biological and pathogenic processes. These aid in detecting neurological disorders, assessing risk, tracking disease progression, and measuring response to therapeutic interventions. Rising incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and others can boost demand for reliable neurological biomarkers. Furthermore, growing focus on development of precision medicine and companion diagnostics for neurological conditions can drive the market growth. However, limited understanding of disease biology and lack of consensus on use of biomarkers can pose challenge to market growth.

Market Dynamics:

Global neurological biomarkers market growth is primarily driven by rising prevalence of neurological disorders globally. According to the data from WHO, neurological disorders affect over a billion people worldwide with neurological conditions being a major contributor to the global burden of disease. Growing geriatric population, prone to these disorders, can boost demand. Higher investments in biomarker research and drug development by pharmaceutical players can drive the market growth. However, high cost of drug development from target identification to commercialization hampers newer biomarkers from entering the market. Lack of consensus on use of biomarkers in diagnosis and clinical decision-making can hamper the market growth. Increasing public private collaborations for interdisciplinary research can offer market growth opportunities.

Key Features of the Study:

This report provides in-depth analysis of the global neurological biomarkers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neurological biomarkers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Qiagen, Thermo Fisher Scientific and Abbott Laboratories
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global neurological biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

By Biomarker Type:
- Artificial Tears
- Imaging Biomarkers
- Metabolomics Biomarkers
- Proteomic Biomarkers
- Genomics Biomarkers
By Application
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Autism Spectrum Disorders
- Others
By End User
- Hospital Laboratories
- Clinical Diagnostic Centers
- Research Organizations
- Others
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Thermo Fisher Scientific Inc.
- Merck & Co., Inc.
- Bio-Rad Laboratories, Inc.
- AbbVie Inc.
- QIAGEN N.V.
- Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Myriad RBM
- Quanterix Corporation
- PerkinElmer Inc.
- Fujirebio
- Alzheon, Inc.
- Diagenic ASA
- Psynova Neurotech Ltd
- Banyan Biomarkers, Inc.
- Cisbio Bioassays
- Athena Diagnostics
- Immuno-Biological Laboratories Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Biomarker Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Neurological Biomarkers Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Neurological Biomarkers Market, By Biomarker Type, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Artificial Tears
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Imaging Biomarkers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Metabolomics Biomarkers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Proteomic Biomarkers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Genomics Biomarkers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Neurological Biomarkers Market, By Application, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Alzheimer's Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parkinson's Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Multiple Sclerosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autism Spectrum Disorders
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Neurological Biomarkers Market, By End User, 2020 - 2032, (USD Bn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Hospital Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Clinical Diagnostic Centers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Research Organizations
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Neurological Biomarkers Market, By Region, 2020 - 2032, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Thermo Fisher Scientific Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bio-Rad Laboratories, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- QIAGEN N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- F. Hoffmann-La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Siemens Healthineers AG
- Myriad RBM
- Quanterix Corporation
- PerkinElmer Inc.
- Fujirebio
- Alzheon, Inc.
- Diagenic ASA
- Psynova Neurotech Ltd
- Banyan Biomarkers, Inc.
- Cisbio Bioassays
- Athena Diagnostics
- Immuno-Biological Laboratories Co., Ltd.